BPC-157 and CJC-1295 (without DAC) Interaction

Synergistic
Mechanism-based 47% confidence

BPC-157 and CJC-1295 (without DAC) have a synergistic interaction with 47% confidence. BPC-157 and CJC-1295 (without DAC) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. These compounds primarily affect different organ systems.

Compound Profiles

BPC-157

Body Protection Compound-157 | Pentadecapeptide

Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways..

Half-life: <30 minutes Typical dose: 250-500mcg healing, longevity
vegf anticoagulantcarcinogenic riskpro angiogenicteratogenic
View full profile

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Combined Organ Load

Blood Vessels
low
GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (BPC-157, CJC-1295 (without DAC)). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (BPC-157, CJC-1295 (without DAC)). Monitor accordingly.

Frequently Asked Questions

Can I take BPC-157 with CJC-1295 (without DAC)?

Yes, BPC-157 and CJC-1295 (without DAC) can generally be taken together. BPC-157 and CJC-1295 (without DAC) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.

Is BPC-157 and CJC-1295 (without DAC) safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: carcinogenic risk, teratogenic. Monitor accordingly.

What are the interactions between BPC-157 and CJC-1295 (without DAC)?

BPC-157 and CJC-1295 (without DAC) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time BPC-157 and CJC-1295 (without DAC)?

BPC-157 has a half-life of <30 minutes and CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: BPC-157 vs CJC-1295 (without DAC)

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.